Liver resection and ablation for squamous cell carcinoma liver metastases
(2021) In BJS Open 5(4).- Abstract
BACKGROUND: Limited evidence exists to guide the management of patients with liver metastases from squamous cell carcinoma (SCC). The aim of this retrospective multicentre cohort study was to describe patterns of disease recurrence after liver resection/ablation for SCC liver metastases and factors associated with recurrence-free survival (RFS) and overall survival (OS). METHOD: Members of the European-African Hepato-Pancreato-Biliary Association were invited to include all consecutive patients undergoing liver resection/ablation for SCC liver metastases between 2002 and 2019. Patient, tumour and perioperative characteristics were analysed with regard to RFS and OS. RESULTS: Among the 102 patients included from 24 European centres, 56... (More)
BACKGROUND: Limited evidence exists to guide the management of patients with liver metastases from squamous cell carcinoma (SCC). The aim of this retrospective multicentre cohort study was to describe patterns of disease recurrence after liver resection/ablation for SCC liver metastases and factors associated with recurrence-free survival (RFS) and overall survival (OS). METHOD: Members of the European-African Hepato-Pancreato-Biliary Association were invited to include all consecutive patients undergoing liver resection/ablation for SCC liver metastases between 2002 and 2019. Patient, tumour and perioperative characteristics were analysed with regard to RFS and OS. RESULTS: Among the 102 patients included from 24 European centres, 56 patients had anal cancer, and 46 patients had SCC from other origin. RFS in patients with anal cancer and non-anal cancer was 16 and 9 months, respectively (P = 0.134). A positive resection margin significantly influenced RFS for both anal cancer and non-anal cancer liver metastases (hazard ratio 6.82, 95 per cent c.i. 2.40 to 19.35, for the entire cohort). Median survival duration and 5-year OS rate among patients with anal cancer and non-anal cancer were 50 months and 45 per cent and 21 months and 25 per cent, respectively. For the entire cohort, only non-radical resection was associated with worse overall survival (hazard ratio 3.21, 95 per cent c.i. 1.24 to 8.30). CONCLUSION: Liver resection/ablation of liver metastases from SCC can result in long-term survival. Survival was superior in treated patients with liver metastases from anal versus non-anal cancer. A negative resection margin is paramount for acceptable outcome.
(Less)
- author
- author collaboration
- organization
- publishing date
- 2021-07-06
- type
- Contribution to journal
- publication status
- published
- subject
- in
- BJS Open
- volume
- 5
- issue
- 4
- publisher
- Wiley
- external identifiers
-
- scopus:85114849312
- pmid:34426830
- ISSN
- 2474-9842
- DOI
- 10.1093/bjsopen/zrab060
- language
- English
- LU publication?
- yes
- id
- 916dea84-97d9-46f5-8d0f-4e9b5a581c1c
- date added to LUP
- 2021-10-11 13:57:56
- date last changed
- 2024-03-23 11:10:18
@article{916dea84-97d9-46f5-8d0f-4e9b5a581c1c,
abstract = {{<p>BACKGROUND: Limited evidence exists to guide the management of patients with liver metastases from squamous cell carcinoma (SCC). The aim of this retrospective multicentre cohort study was to describe patterns of disease recurrence after liver resection/ablation for SCC liver metastases and factors associated with recurrence-free survival (RFS) and overall survival (OS). METHOD: Members of the European-African Hepato-Pancreato-Biliary Association were invited to include all consecutive patients undergoing liver resection/ablation for SCC liver metastases between 2002 and 2019. Patient, tumour and perioperative characteristics were analysed with regard to RFS and OS. RESULTS: Among the 102 patients included from 24 European centres, 56 patients had anal cancer, and 46 patients had SCC from other origin. RFS in patients with anal cancer and non-anal cancer was 16 and 9 months, respectively (P = 0.134). A positive resection margin significantly influenced RFS for both anal cancer and non-anal cancer liver metastases (hazard ratio 6.82, 95 per cent c.i. 2.40 to 19.35, for the entire cohort). Median survival duration and 5-year OS rate among patients with anal cancer and non-anal cancer were 50 months and 45 per cent and 21 months and 25 per cent, respectively. For the entire cohort, only non-radical resection was associated with worse overall survival (hazard ratio 3.21, 95 per cent c.i. 1.24 to 8.30). CONCLUSION: Liver resection/ablation of liver metastases from SCC can result in long-term survival. Survival was superior in treated patients with liver metastases from anal versus non-anal cancer. A negative resection margin is paramount for acceptable outcome.</p>}},
author = {{Engstrand, J. and Abreu de Carvalho, L. F. and Aghayan, D. and Balakrishnan, A. and Belli, A. and Björnsson, B. and Dasari, B. V.M. and Detry, O. and Di Martino, M. and Edwin, B. and Erdmann, J. and Fristedt, R. and Fusai, G. and Gimenez-Maurel, T. and Hemmingsson, O. and Hidalgo Salinas, C. and Isaksson, B. and Ivanecz, A. and Izzo, F. and Knoefel, W. T. and Kron, P. and Lehwald-Tywuschik, N. and Lesurtel, M. and Lodge, J. P.A. and Machairas, N. and Marino, M. V. and Martin, V. and Paterson, A. and Rystedt, J. and Sandström, P. and Serrablo, A. and Siriwardena, A. K. and Taflin, H. and van Gulik, T. M. and Yaqub, S. and Özden, I. and Ramia, J. M. and Sturesson, C.}},
issn = {{2474-9842}},
language = {{eng}},
month = {{07}},
number = {{4}},
publisher = {{Wiley}},
series = {{BJS Open}},
title = {{Liver resection and ablation for squamous cell carcinoma liver metastases}},
url = {{http://dx.doi.org/10.1093/bjsopen/zrab060}},
doi = {{10.1093/bjsopen/zrab060}},
volume = {{5}},
year = {{2021}},
}